ema glp-1 vision loss recommendation 2025 Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says Indiana woman reports vision loss
Description
A recent review in Diabetes Care evaluates the efficacy and safety of GLP-1 receptor agonists for type 2 diabetes and obesity, exploring their potential for new medical indications.

GLP-1

A new study provides the first clinical evidence that popular semaglutide drugs, like Ozempic or Wegovy, could slow down processes associated with biological aging.
Physician-supervised compounded semaglutide weight loss with DEXA body composition tracking

What really happens when patients stop GLP-1s like semaglutide or tirzepatide

Simply apply once daily and enjoy steady support as part of your balanced lifestyle
